Avidity Partners Management LP Grows Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Avidity Partners Management LP boosted its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 597.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 192,400 shares of the company's stock after buying an additional 164,800 shares during the period. Avidity Partners Management LP owned approximately 0.57% of TransMedics Group worth $11,996,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Atlas Capital Advisors Inc. bought a new position in shares of TransMedics Group during the 4th quarter valued at approximately $31,000. Hager Investment Management Services LLC bought a new position in TransMedics Group during the fourth quarter valued at $33,000. Sachetta LLC purchased a new position in shares of TransMedics Group in the 4th quarter worth $40,000. AlphaQuest LLC bought a new stake in shares of TransMedics Group in the 4th quarter worth about $52,000. Finally, Arcadia Investment Management Corp MI purchased a new stake in shares of TransMedics Group during the 4th quarter valued at about $72,000. Hedge funds and other institutional investors own 99.67% of the company's stock.

Analysts Set New Price Targets

TMDX has been the topic of several analyst reports. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research note on Wednesday, April 23rd. Piper Sandler reissued an "overweight" rating and set a $105.00 target price (up previously from $90.00) on shares of TransMedics Group in a research report on Tuesday, April 29th. Finally, Canaccord Genuity Group restated a "buy" rating and issued a $104.00 price target on shares of TransMedics Group in a research report on Tuesday, March 11th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $124.20.

TransMedics Group Stock Performance

Shares of TMDX traded up $2.51 during trading hours on Wednesday, reaching $95.89. 951,486 shares of the company traded hands, compared to its average volume of 1,325,497. The stock has a market capitalization of $3.24 billion, a P/E ratio of 102.01 and a beta of 1.91. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The business has a fifty day moving average price of $76.81 and a 200-day moving average price of $75.88. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.